PMC:7556165 / 68847-69163 JSONTXT

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T190","span":{"begin":275,"end":282},"obj":"Chemical"}],"attributes":[{"id":"A190","pred":"chebi_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T385","span":{"begin":160,"end":165},"obj":"Species"}],"attributes":[{"id":"A385","pred":"ncbi_taxonomy_id","subj":"T385","obj":"NCBItxid:9606"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T406","span":{"begin":0,"end":111},"obj":"Sentence"},{"id":"T407","span":{"begin":112,"end":316},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1880","span":{"begin":87,"end":91},"obj":"Gene"},{"id":"1881","span":{"begin":166,"end":171},"obj":"Gene"},{"id":"1882","span":{"begin":227,"end":231},"obj":"Gene"},{"id":"1883","span":{"begin":273,"end":282},"obj":"Gene"},{"id":"1884","span":{"begin":160,"end":165},"obj":"Species"},{"id":"1885","span":{"begin":101,"end":110},"obj":"Disease"},{"id":"1959","span":{"begin":166,"end":171},"obj":"Gene"},{"id":"1964","span":{"begin":160,"end":165},"obj":"Species"}],"attributes":[{"id":"A1964","pred":"pubann:denotes","subj":"1964","obj":"Tax:9606"},{"id":"A1881","pred":"pubann:denotes","subj":"1881","obj":"Gene:59272"},{"id":"A1882","pred":"pubann:denotes","subj":"1882","obj":"Gene:59272"},{"id":"A1885","pred":"pubann:denotes","subj":"1885","obj":"MESH:D007239"},{"id":"A1959","pred":"pubann:denotes","subj":"1959","obj":"Gene:59272"},{"id":"A1884","pred":"pubann:denotes","subj":"1884","obj":"Tax:9606"},{"id":"A1883","pred":"pubann:denotes","subj":"1883","obj":"Gene:43740568"},{"id":"A1880","pred":"pubann:denotes","subj":"1880","obj":"Gene:59272"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T6121","span":{"begin":87,"end":91},"obj":"Protein"},{"id":"T6122","span":{"begin":166,"end":169},"obj":"Protein"},{"id":"T6147","span":{"begin":227,"end":231},"obj":"Protein"},{"id":"T6148","span":{"begin":273,"end":282},"obj":"Protein"}],"attributes":[{"id":"A6121","pred":"uniprot_id","subj":"T6121","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A6122","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9GLN7"},{"id":"A6123","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9GLN6"},{"id":"A6124","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9EQM9"},{"id":"A6125","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q8CFN1"},{"id":"A6126","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q7TMC6"},{"id":"A6127","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q7M4L4"},{"id":"A6128","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q6GTS2"},{"id":"A6129","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q59GY8"},{"id":"A6130","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q53YX9"},{"id":"A6131","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q50JE5"},{"id":"A6132","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q10751"},{"id":"A6133","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q0GA41"},{"id":"A6134","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P47820"},{"id":"A6135","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22968"},{"id":"A6136","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22967"},{"id":"A6137","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P22966"},{"id":"A6138","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12822"},{"id":"A6139","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12821"},{"id":"A6140","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P12820"},{"id":"A6141","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/P09470"},{"id":"A6142","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/O02852"},{"id":"A6143","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/E7EU16"},{"id":"A6144","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/B4DXI3"},{"id":"A6145","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/B0LPF0"},{"id":"A6146","pred":"uniprot_id","subj":"T6122","obj":"https://www.uniprot.org/uniprot/Q9VJV3"},{"id":"A6147","pred":"uniprot_id","subj":"T6147","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A6148","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/Q9D080"},{"id":"A6149","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/Q9BSH7"},{"id":"A6150","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/Q91X32"},{"id":"A6151","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/Q8VII4"},{"id":"A6152","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/Q5SYG4"},{"id":"A6153","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/P48819"},{"id":"A6154","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/P29788"},{"id":"A6155","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/P22458"},{"id":"A6156","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/P04004"},{"id":"A6157","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/P01141"},{"id":"A6158","pred":"uniprot_id","subj":"T6148","obj":"https://www.uniprot.org/uniprot/B2R7G0"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T277","span":{"begin":101,"end":110},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T278","span":{"begin":304,"end":308},"obj":"http://purl.obolibrary.org/obo/IDO_0000531"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T451","span":{"begin":275,"end":282},"obj":"Body_part"}],"attributes":[{"id":"A451","pred":"fma_id","subj":"T451","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T406","span":{"begin":101,"end":110},"obj":"Disease"}],"attributes":[{"id":"A406","pred":"mondo_id","subj":"T406","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T146","span":{"begin":283,"end":308},"obj":"http://purl.obolibrary.org/obo/GO_0051701"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T151","span":{"begin":283,"end":308},"obj":"http://purl.obolibrary.org/obo/GO_0051701"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1880","span":{"begin":87,"end":91},"obj":"Gene"},{"id":"1881","span":{"begin":166,"end":171},"obj":"Gene"},{"id":"1882","span":{"begin":227,"end":231},"obj":"Gene"},{"id":"1883","span":{"begin":273,"end":282},"obj":"Gene"},{"id":"1884","span":{"begin":160,"end":165},"obj":"Species"},{"id":"1885","span":{"begin":101,"end":110},"obj":"Disease"}],"attributes":[{"id":"A1880","pred":"tao:has_database_id","subj":"1880","obj":"Gene:59272"},{"id":"A1881","pred":"tao:has_database_id","subj":"1881","obj":"Gene:59272"},{"id":"A1882","pred":"tao:has_database_id","subj":"1882","obj":"Gene:59272"},{"id":"A1883","pred":"tao:has_database_id","subj":"1883","obj":"Gene:43740568"},{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"Tax:9606"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}

{"project":"LitCovid-sentences","denotations":[{"id":"T406","span":{"begin":0,"end":111},"obj":"Sentence"},{"id":"T407","span":{"begin":112,"end":316},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"FIGURE 10 Schematic representation of the potential therapeutic approaches to address ACE2 mediated infection. Exogenous administration of soluble recombinant human ACE 2 sequesters circulating viral particles, while specific ACE2 blockers bind the receptor, impeding the S-protein interaction with the host target."}